Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Estudio de fase II, de búsqueda de dosis, doble ciego, aleatorizado, controlado con placebo, que compara diferentes dosis de las cápsulas ZED1227 frente a placebo en el tratamiento de la enfermedad del hígado graso no alcohólico (NAFLD) con fibrosis significativa

Contact
  • Protocol code: CEC-11/NAS
  • EudraCT code: 2021-002253-29
  • Pathology: Malalties del sistema digestiu
  • Principal investigator:  Pericàs Pulido, Juan Manuel
  • Research group:  Malalties hepàtiques
  • Service: Hepatologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Minimización de la 17b-hidroxiesteroide deshidrogenasa tipo 13 para el tratamiento de EHNA (HORIZON): Estudio Fase 2b, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de GSK4532990 en adultos con esteatohepatitis no alcohólica precirrótica.

Contact
  • Protocol code: 218672
  • EudraCT code: 2022-002538-14
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Pericàs Pulido, Juan Manuel
  • Research group:  Malalties hepàtiques
  • Service: Hepatologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase II, aleatorizado, doble ciego, comparativo con placebo y de búsqueda de dosis para evaluar la eficacia y la seguridad de TAK-062 para el tratamiento de la celiaquía activa en participantes que siguen una dieta sin gluten

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase IIb, aleatorizado, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia, la seguridad, la tolerabilidad y el perfil de resistencia de GSK3640254 en combinación con dolutegravir en comparación con dolutegravir más lamivudina en adultos infectados por el VIH-1 sin tratamiento previo

Contact
  • Protocol code: 212483
  • EudraCT code: 2021-000016-28
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Curran Fàbregas, Adria
  • Research group:  Malalties infeccioses
  • Service: Infeccioses
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio doble ciego para participante e investigador de un mes de duración en el que se evalúan la eficacia y la seguridad de remibrutinib (LOU064) en varios niveles de dosis en participantes adultos con alergia al cacahuete.

Contact
  • Protocol code: CLOU064I12201
  • EudraCT code: 2021-006950-30
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Labrador Horrillo, Moisés
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y multicéntrico para evaluar la eficacia, la seguridad y la tolerabilidad de JNJ-40411813 como tratamiento complementario en sujetos con crisis epilépticas de inicio focal con respuesta subóptima a levetiracetam.

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Nuevos criterios de valoración clínica en pacientes con síndrome de Sjögren primario (SSp): un ensayo de intervención basado en la estratificación de los pacientes.

Contact
  • Protocol code: APHP190131
  • EudraCT code: 2019-002470-32
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Solans Laque, Roser
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio Fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de la administración de bepirovirsen en pacientes con Hepatitis B crónica HBeAg negativos y en tratamiento con análogos de nucleós(t)idos (B-Well 1)

Contact
  • Protocol code: 202009
  • EudraCT code: 2021-005139-22
  • Pathology: Certes afeccions originades en el període perinatal
  • Principal investigator:  Buti Ferret, Maria
  • Research group:  Malalties hepàtiques
  • Service: Hepatologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase I/II multicéntrico en el que se evalúan la eficacia y la seguridad de ribociclib (LEE011) en combinación con topotecán y temozolomida (TOTEM) en pacientes pediátricos con neuroblastoma recidivante o refractario y otros tumores sólidos

Contact

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de 52 semanas, aleatorizado, con enmascaramiento doble, controlado con placebo, con grupos paralelos, para evaluar la eficacia y la seguridad de dos dosis de CHF6001 administradas con inhalador de polvo seco (DPI) como complemento a un tratamiento triple de mantenimiento de sujetos con enfermedad pulmonar obstructiva crónica (EPOC) y bronquitis crónica

Contact
  • Protocol code: CLI-06001AA1-04
  • EudraCT code: 2020-003666-40
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Martí Beltran, Sergi
  • Research group:  Pneumologia
  • Service: Pneumologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Subscribe to